1 Ocak 2017 Dergi makalesi Açık Erişim

Timur, Selin Seda; Bhattarai, Prashant; Gursoy, Reyhan Neslihan; Vural, Imran; Khaw, Ban-An

Dublin Core

<?xml version='1.0' encoding='utf-8'?>
<oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
  <dc:creator>Timur, Selin Seda</dc:creator>
  <dc:creator>Bhattarai, Prashant</dc:creator>
  <dc:creator>Gursoy, Reyhan Neslihan</dc:creator>
  <dc:creator>Vural, Imran</dc:creator>
  <dc:creator>Khaw, Ban-An</dc:creator>
  <dc:date>2017-01-01</dc:date>
  <dc:description>Purpose LyP-1, a nine-amino-acid tumor homing peptide, selectively binds to its cognate receptor, p32. Overexpression of p32 in certain tumors should allow use of LyP-1 as a targeting agent for the delivery of therapeutic or diagnostic agents. Peptide conjugates are developed for enhanced pretargeting of MDA-MB-231 breast cancer cells with peptideantibody bispecific complexes and targeting with multipledrug/- fluorophore-conjugated nano-polymers.</dc:description>
  <dc:identifier>https://aperta.ulakbim.gov.trrecord/47829</dc:identifier>
  <dc:identifier>oai:zenodo.org:47829</dc:identifier>
  <dc:rights>info:eu-repo/semantics/openAccess</dc:rights>
  <dc:rights>http://www.opendefinition.org/licenses/cc-by</dc:rights>
  <dc:source>PHARMACEUTICAL RESEARCH 34(2) 352-364</dc:source>
  <dc:title>Design and In Vitro Evaluation of Bispecific Complexes and Drug Conjugates of Anticancer Peptide, LyP-I in Human Breast Cancer</dc:title>
  <dc:type>info:eu-repo/semantics/article</dc:type>
  <dc:type>publication-article</dc:type>
</oai_dc:dc>